R
Richard J. O. Barnard
Researcher at Merck & Co.
Publications - 58
Citations - 2775
Richard J. O. Barnard is an academic researcher from Merck & Co.. The author has contributed to research in topics: Ribavirin & Boceprevir. The author has an hindex of 21, co-authored 57 publications receiving 2470 citations. Previous affiliations of Richard J. O. Barnard include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox,Edwin DeJesus,Adriano Lazzarin,Richard B. Pollard,José Valdez Madruga,Daniel S Berger,Jing Zhao,Xia Xu,Angela Williams-Diaz,Anthony Rodgers,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Peter Sklar +15 more
TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.
Journal ArticleDOI
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Joseph J. Eron,Benjamin Young,David A. Cooper,Mike Youle,Edwin DeJesus,Jaime Andrade-Villanueva,Cassy Workman,Roberto Zajdenverg,Gerd Fätkenheuer,Daniel S Berger,Princy Kumar,Anthony Rodgers,Melissa Shaughnessy,Monica L. Walker,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Xia Xu,Peter Sklar +20 more
TL;DR: Although switching to raltegravir was associated with greater reductions in serum lipid concentrations than was continuation of lopinavir-ritonavir, efficacy results did not establish non-inferiority of ral Teva, and the studies were terminated at week 24 because of lower than expected virological efficacy.
Journal ArticleDOI
A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals
Francesco A. Procopio,Rémi Fromentin,Deanna A. Kulpa,Jessica H. Brehm,Anne-Gaelle Bebin,Matthew C. Strain,Douglas D. Richman,Una O'Doherty,Sarah Palmer,Sarah Palmer,Frederick Hecht,Rebecca Hoh,Richard J. O. Barnard,Michael D. Miller,Daria J. Hazuda,Steven G. Deeks,Rafick-Pierre Sekaly,Nicolas Chomont +17 more
TL;DR: The development of a novel assay that measures the magnitude of the latent HIV reservoir, the main barrier to HIV eradication, is described, which suggests that TILDA is a reproducible and sensitive approach to measure the frequency of productively and latently infected cells in clinical settings.
Journal ArticleDOI
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox,Edwin DeJesus,Daniel S Berger,Adriano Lazzarin,Richard B. Pollard,José Valdez Madruga,Jing Zhao,Hong Wan,Christopher L. Gilbert,Hedy Teppler,Anthony Rodgers,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Peter Sklar +16 more
TL;DR: When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir exhibited durable antiretroviral activity that was noninferior to the efficacy of efavirenz through 96 weeks of therapy.
Journal ArticleDOI
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T. Steigbigel,David A. Cooper,Hedy Teppler,Joseph J. Eron,José M. Gatell,Princy Kumar,Jürgen K. Rockstroh,Mauro Schechter,Christine Katlama,Martin Markowitz,Patrick Yeni,Mona Loutfy,Adriano Lazzarin,Jeffrey L. Lennox,Bonaventura Clotet,Jing Zhao,Hong Wan,Rand R. Rhodes,Kim M. Strohmaier,Richard J. O. Barnard,Robin Isaacs,Bach-Yen Nguyen +21 more
TL;DR: Raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimizing background therapy alone.